Controlling rheumatic heart disease in developing countries

Cardiovascular Journal of South Africa

Volumn 17, Issue 4, 2006, Pages 164-165

  Carapetis, Jonathan R ^a,b   Mayosi, Bongani M ^a,c   Kaplan, Edward L ^b,d  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b WORLD HEART FEDERATION   (Switzerland)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENZATHINE PENICILLIN; PENICILLIN DERIVATIVE; STREPTOCOCCUS VACCINE;

COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISEASE CONTROL; EDITORIAL; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; MEDICAL SOCIETY; MORBIDITY; MORTALITY; PREVALENCE; PROPHYLAXIS; RHEUMATIC HEART DISEASE; SCREENING TEST; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; WORLD HEALTH ORGANIZATION;

DEVELOPING COUNTRIES; HUMANS; MYOCARDIAL ISCHEMIA; RHEUMATIC HEART DISEASE; STREPTOCOCCAL INFECTIONS;

EID: 33750959038     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (11)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5: 685-694.
2. Carapetis JR, Currie BJ. Mortality due to acute rheumatic fever and rheumatic heart disease in the Northern Territory: a preventable cause of death in aboriginal people. Aust NZ J Publ Hlth 1999; 23: 159-163.
3. AIHW: Field B. Rheumatic heart disease: all but forgotten in Australia except among Aboriginal and Torres Strait Islander peoples. Canberra: AIHW, 2004.
4. Kotloff KL, Corretti M, Palmer K, et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. J Am Med Assoc 2004; 292: 709-715.
5. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70: 2171-2177.
6. Carapetis JR. Group A streptococcal vaccine development: current status and issues of relevance to less developed countries. WHO/FCH/CAH/05.09. Geneva: World Health Organisation, 2004: 1-24.
7. WHO expert consultation on rheumatic fever and rheumatic heart disease (2001: Geneva Switzerland). Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation, Geneva, 29 October - 1 November 2001. Geneva: World Health Organisation, 2004.
8. McDonald M, Brown A, Noonan S, Carapetis JR. Preventing recurrent rheumatic fever: the role of register based programmes. Heart 2005; 91: 1131-1133.
9. WHO Cardiovascular Diseases Unit and principal investigators. WHO programme for the prevention and control of rheumatic fever/rheumatic heart disease in 16 developing countries: report from Phase I (1986-90). Bull Wld Hlth Organ 1992; 70: 213-218.
10. Robertson KA, Volmink JA, Mayosi BM. Towards a uniform plan for the control of rheumatic fever and rheumatic heart disease in Africa - the Awareness Surveillance Advocacy Prevention (ASAP) programme. S Afr Med J 2006; 96: 241-245.
11. Mayosi B, Robertson K, Volmink J, et al. The Drakensberg declaration on the control of rheumatic fever and rheumatic heart disease in Africa. S Afr Med J 2006; 96: 246.